PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10730343

[Controlled viral risks].

F Barin
View original source ↗Export metadata ↓

Abstract

The prevalence of virological markers in blood donors has been continuously decreasing since the implementation, as soon as they were available, of serological screening methods. In 1998, the prevalences (per 10,000 donations) were 0.17 for antibody to HIV, 0.08 for antibody to HTLV, 2.23 for HBs Ag and 2.52 for antibody to HCV. The values are of course higher in new donors when compared to regular donors: approximately five-fold for HIV, 50-fold for HCV and 300-fold for HBs Ag. The remaining major questions concern the residual risk due to infectious donations which could escape the preventive measures. It seems evident that the major risk is imputable mainly to donations collected during the window period. During the 1996-1998 period, the residual risk for HIV was one out of 1,350,000 donations, 0 for HTLV, one out of 375,000 for HCV, and one out of 220,000 for HBV. A few cases of 'immuno-silent' patients have been reported. They remain exceptional. The first data collected after implementation of Nucleic Acid Technology (NAT) confirm the very low residual risk. The molecular epidemiology of the concerned viruses applied to the evaluation of screening assays highlighted the impact of the genetic diversity on the efficiency of these assays. This is particularly evident for HIV and HBV. The recent introduction of leucodepletion probably brought an important contribution in diminishing the risk of transmission of leucotropic viruses such as cytomegalovirus, Epstein-Barr viruses, human herpesviruses 6 and 7, and HTLV. If the purification process of plasma derived medicinal products including inactivation procedures permits confidence in the elimination of infectivity due to enveloped viruses, the detection of nucleic acid sequences derived from naked viruses in plasma pools may greatly contribute to their safety.

Explore related subjects

Antibodies, ViralAntigens, ViralBiomarkersBlood Component TransfusionBlood DonorsBlood TransfusionDNA, ViralDeltaretrovirus InfectionsHIV InfectionsHepatitis, Viral, HumanHumansLeukocytesMass ScreeningPrevalenceRNA, ViralRiskSeroepidemiologic StudiesTransfusion ReactionViremiaVirus DiseasesJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Barin. 2000. [Controlled viral risks].. https://doi.org/10.1016/s1246-7820(00)88708-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Opioids, opioid receptors, and the immune response.

It is now clear that opioid receptors participate in the function of the cells of the immune system, and evidence suggests that opioids modulate both innate and acquired immune responses. We review literature here which establishes that mu-, kappa-, and delta-opioid compounds alter resistance to a variety of infectious agents, including the Human Immunodeficiency Virus (HIV). The nature of the immunomodulatory activity of the opioids has been the subject of a great deal of research over the last ten years. There is increasing evidence that effects of opioids on the immune response are mediated at several levels. Modulation of the inflammatory response appears to be a target of these compounds, including effects on phagocytic activity, as well as the response of cells to various chemoattractant molecules. Moreover, findings from several laboratories have demonstrated the impact of opioid treatment on antibody responses, and the molecular basis for this effect is likely due, at least in part, to the modulation of both cytokine and cytokine receptor expression. Future research should provide a clearer understanding of the cellular and molecular targets of opioid action within the immune system.

Antibodies, Viral↗
PubMed2001

Antibody inhibition of the transcriptase activity of the rotavirus DLP: a structural view.

On entering the host cell the rotavirus virion loses its outer shell to become a double-layered particle (DLP). The DLP then transcribes the 11 segments of its dsRNA genome using its own transcriptase complex, and the mature mRNA emerges along the 5-fold axis. In order to better understand the transcription mechanism and the role of VP6 in transcription we have studied three monoclonal antibodies against VP6: RV-238 which inhibits the transcriptase activity of the DLP; and RV-133 and RV-138 which have no effect on transcription. The structures obtained by cryo-electron microscopy of the DLP/Fab complexes and by X-ray crystallography of the VP6 trimer and the VP6/Fab-238 complex have been combined to give pseudo-atomic structures. Steric hindrance between the Fabs results in limited Fab occupancy. In particular, there are on average only three of a possible five Fabs-238 which point towards the 5-fold axis. Thus, Fabs-238 are not in a position to block the exiting mRNA, nor is there any visible conformational change in VP6 on antibody binding at a resolution of 23 A. However, the epitope of the inhibiting antibody involves two VP6 monomers, whereas, those of the non-inhibiting antibodies have an epitope on only one VP6. Thus, the inhibition of transcription may be a result of inhibition of a possible change in the VP6 conformation associated with the transcription of mRNA.

Antibodies, Viral↗
PubMed2001

Detection and subcellular localization of the turnip yellow mosaic virus 66K replication protein in infected cells.

Turnip yellow mosaic virus (TYMV) encodes a 206-kDa (206K) polyprotein with domains of methyltransferase, proteinase, NTPase/helicase, and RNA-dependent RNA polymerase (RdRp). In vitro, the 206K protein has been shown to undergo proteolytic processing, giving rise to the synthesis of 140-kDa (140K) and 66-kDa (66K) proteins, the latter comprising the RdRp protein domain. Antibodies were raised against the 66K protein and were used to detect the corresponding viral protein in infected cells; both leaf tissues and protoplasts were examined. The antiserum specifically recognized a protein of approximately 66 kDa, indicating that the cleavage observed in vitro is also functional in vivo. The 66K protein accumulates transiently during protoplast infection and localizes to cellular membrane fractions. Indirect immunofluorescence assays and electron microscopy of immunogold-decorated ultrathin sections of infected leaf tissue using anti-66K-specific antibody revealed labeling of membrane vesicles located at the chloroplast envelope.

Antibodies, Viral↗